Revolution Medicines officer plans $1.1M stock sale

Revolution Medicines, Inc. (RVMD) reported that officer Stephen Michael Kelsey filed a notice of proposed sale under Rule 144 for 5,415 shares of common stock expected from RSU vesting on September 15, 2026, to be held at E*TRADE Financial Corporation.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) reported that officer Stephen Michael Kelsey filed a notice of proposed sale under Rule 144 for 5,415 shares of common stock expected from RSU vesting on September 15, 2026, to be held at E*TRADE Financial Corporation.

The notice also lists recent sales of Revolution Medicines common stock for Kelsey’s account, including 92,531 shares on September 11, 2026 with a transaction value of $18,724,767.48, and 4,175 shares on June 16, 2026 with a transaction value of $651,797.66.

Key Figures

Proposed shares to be sold: 5,415 shares Proposed transaction value: $1,103,414.55 Recent sale shares: 92,531 shares +3 more

6 metrics

Proposed shares to be sold 5,415 shares Common stock associated with RSU vesting dated September 15, 2026

Proposed transaction value $1,103,414.55 Value listed for 5,415 common shares with E*TRADE Financial Corporation

Recent sale shares 92,531 shares Common stock sold on September 11, 2026

Recent sale value $18,724,767.48 Transaction value for 92,531 common shares on September 11, 2026

Earlier sale shares 4,175 shares Common stock sold on June 16, 2026

Earlier sale value $651,797.66 Transaction value for 4,175 common shares on June 16, 2026

Key Terms

Rule 144, RSU vesting, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU vesting financial

"Common Stock | 09/15/2026 | RSU vesting | Issuer"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

attorney-in-fact regulatory

"Signature | Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Revolution Medicines (RVMD)?

It discloses that officer Stephen Michael Kelsey filed a Rule 144 notice to sell 5,415 shares of Revolution Medicines common stock expected from RSU vesting on September 15, 2026, held through E*TRADE Financial Corporation.

How many RVMD shares are proposed to be sold under this Rule 144 notice?

The notice covers a proposed sale of 5,415 shares of Revolution Medicines common stock, associated with RSU vesting and listed with an effective date of September 15, 2026.

What recent RVMD stock sales by Stephen Michael Kelsey are reported?

The filing lists sales of 92,531 shares of Revolution Medicines common stock on September 11, 2026 for $18,724,767.48, and 4,175 shares on June 16, 2026 for $651,797.66.

Which broker is involved in the proposed RVMD share sale?

The proposed sale of 5,415 shares of Revolution Medicines common stock is listed through E*TRADE Financial Corporation, located in Alpharetta, Georgia.

Who signed the Form 144 related to RVMD and in what capacity?

The Form 144 is signed by Jack Anders, acting as attorney-in-fact for Stephen Michael Kelsey, on a signature line dated May 31, 2023 with a filing-related date of September 15, 2026 also shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 06:09 PM Accepted by SEC EDGAR 09/15/2026 - 06:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001462808
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Revolution Medicines, Inc.
SEC File Number	001-39219
Address of Issuer	700 Saginaw Drive Redwood City CALIFORNIA 94063
Phone	650-481-6801
Name of Person for Whose Account the Securities are To Be Sold	Kelsey Stephen Michael
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	5415	1103414.55	214336418	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/15/2026	RSU vesting	Issuer			5415	09/15/2026	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	09/11/2026	92531	18724767.48
Stephen Michael Kelsey c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/16/2026	4175	651797.66

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/31/2023
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)